These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 17901213)

  • 21. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
    Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
    Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
    Nuijten M; Lebmeier M; Wittenberg W
    J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus infection and palivizumab: are families receiving accurate information?
    Weiner JH
    Am J Perinatol; 2010 Mar; 27(3):219-23. PubMed ID: 19784911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
    Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
    Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A health care management company's experience with palivizumab--1 year later.
    Silverman W
    Manag Care; 2003 May; 12(5):49-50. PubMed ID: 12800748
    [No Abstract]   [Full Text] [Related]  

  • 26. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 27. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2010; 16(1):59-66. PubMed ID: 20044846
    [No Abstract]   [Full Text] [Related]  

  • 28. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
    Meberg A; Bruu AL
    Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Passive immunisation of preterm infants with palivizumab against RSV infection.
    Harkensee C; Brodlie M; Embleton ND; Mckean M
    J Infect; 2006 Jan; 52(1):2-8. PubMed ID: 16236360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost minimisation of RSV prevention with palivizumab.
    Wills S; Simpson JH; Coutts J
    Arch Dis Child; 2006 Aug; 91(8):717. PubMed ID: 16861501
    [No Abstract]   [Full Text] [Related]  

  • 31. [Respiratory syncytial virus infections and preventive options].
    Moll HA; de Groot R
    Ned Tijdschr Geneeskd; 2000 Apr; 144(15):724-5. PubMed ID: 10778722
    [No Abstract]   [Full Text] [Related]  

  • 32. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.
    Rackham OJ; Thorburn K; Kerr SJ
    Cardiol Young; 2005 Jun; 15(3):251-5. PubMed ID: 15865826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
    Robinson JL
    Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
    [No Abstract]   [Full Text] [Related]  

  • 35. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic results of palivizumab prophylaxis using vial sharing on immunisation days.
    Ovalı F; Gürsoy T; Erçin S; Yavuzcan Öztürk D; Karatepe HÖ; Karatekin G
    J Paediatr Child Health; 2013 Feb; 49(2):159. PubMed ID: 23418714
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
    Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
    Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.
    Hand IL; Noble L; Geiss D; Shotkin A
    Pediatr Infect Dis J; 2008 Feb; 27(2):175-6. PubMed ID: 18174866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of cost-effectiveness of palivizumab for respiratory syncytial virus.
    Hussman JM; Li A; Paes B; Lanctôt KL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):553-67. PubMed ID: 23140255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.
    Kamal-Bahl S; Doshi J; Campbell J
    Arch Pediatr Adolesc Med; 2002 Oct; 156(10):1034-41. PubMed ID: 12361451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.